pharma
Amarin Neuroscience
Amarin Neuroscience Ltd
Amarin Neuroscience is a pharma organization headquartered in GB. NovaPharmaNews links 0 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO s
Company details
- Status
- Public
- HQ
- GB
- Programs
- 0
- Drugs
- 0
- Patents
- 11
Quick answer
Amarin Neuroscience is a pharma organization headquartered in GB. NovaPharmaNews links 0 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.
Company snapshot
Amarin Neuroscience is a pharma organization headquartered in GB. NovaPharmaNews links 0 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.
- 11 US patent(s) indexed to this assignee profile.
- 3 patent(s) expiring within 24 months — LOE risk lower.
Public regulatory, clinical, patent, and corporate records for Amarin Neuroscience. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
STAT Supreme Court backs generic drugmaker in 'skinny labeling' case: Implications for pharma BD and investors
Recent coverage
Generic Drugmakers Gain Key Victory in ‘Skinny Label’ Patent Case
The US Supreme Court unanimously ruled that Hikma Pharmaceuticals did not infringe Amarin's patents in a skinny-label case, overturning a lower court decision. This decision makes generic drugmakers less vulnerable to lawsuits over skinny labels, preserving a key pathway for early market entry on unpatented indications.
STAT Supreme Court backs generic drugmaker in 'skinny labeling' case: Implications for pharma BD and investors
The U.S. Supreme Court unanimously ruled that Hikma Pharmaceuticals did not infringe Amarin's patents through its skinny-labeled generic version of Vascepa. This decision clarifies the Hatch-Waxman skinny-label safe harbor, reducing litigation risk for generic entrants and reshaping competitive dynamics for branded cardiovascular drugs.
Momentum
Proprietary activity score for Amarin Neuroscience.
1 active signal
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Recent activity
Latest pipeline, patent, and corporate events for Amarin Neuroscience.
- Patent grant
- Patent grant
USE OF COENZYME Q AND EICOSAPENTAENOIC ACID (EPA) FOR THE PREPARATION OF MEDICAMENTS
- Patent grant
- Patent grant
TRAITEMENT DE LA DEPRESSION MELANCOLIQUE SEVERE A L'AIDE D'EPA
- Patent grant
HIGHLY PURIFIED ETHYL EPA AND OTHER EPA DERIVATIVES FOR NEUROLOGICAL DISORDERS
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Amarin Neuroscience?
-
Is Amarin Neuroscience publicly traded?
-
What drugs does Amarin Neuroscience develop or market?
-
What are the latest developments for Amarin Neuroscience?
-
What therapeutic areas does Amarin Neuroscience focus on?